

INDEX

A

- Adaptive immunity.....3, 5, 10, 301
- Adjuvants.....20
- Affinity purification.....43, 168, 170, 175–176, 178, 254
- Antibodies 2, 60, 80, 104, 119, 137, 153, 167, 183, 199, 216, 236, 248, 261, 288, 302, 310, 328, 333, 354, 372
- Antigen discovery.....32, 33, 181–197
- Antigenicity.....30, 31, 353–367
- Antigen identification27, 59–76, 120, 126, 134, 167–180, 195–196
- Antigens 25, 59, 119, 138, 167, 182, 199, 213, 237, 246, 287, 327, 333, 354, 373
- Autoantibodies 28, 30, 33, 60, 199–204

B

- Bacteriophage lambda 181, 183, 186, 188
- Bead array.....79–92
- Biomarker validation372
- Biomarkers25, 28–30, 32, 34, 36, 39, 45, 60, 83, 96, 103–105, 120, 199, 259, 327–332, 371–376
- Breakdown products.....161

C

- Cancer antigens 27, 34
- Cancers.....v, 11, 25, 60, 80, 96, 103, 199, 214, 235, 245, 259, 269, 327, 333
- CD4+T cell epitope mapping..... 215, 217
- Cell activation..... 16, 18, 215–217, 287, 314–316
- Checkpoint..... 13, 21, 374
- Chemical derivatization.....247–249
- Chemokines..... 6, 11, 35, 37, 79–92
- Chimeric antigen receptor T cell therapies (CAR-T).....22
- Crosslinking167–180
- Cytokines 2, 6, 8, 11, 13, 14, 16–18, 35–39, 45, 79–92, 287, 310, 315, 322, 340

D

- Dissolution of immunoprecipitates.....119
- Druggable.....310, 311, 317–321

E

- Electroimmunoprecipitation..... 35, 119–120, 125, 126, 133

- Epitopes 26, 133, 138, 161, 182, 200, 213, 245, 287, 302, 310, 328, 356
- Evidence based medicine.....372–374
- Extravasation 310–312, 321

F

- Flow cytometry 229, 374
- Francisella* 61, 288

G

- GalNAc200, 202–205, 209
- Genomic DNA display.....183
- Glycopeptide analysis279
- Glycopeptide microarray 199–204
- Glycosylation.....30, 33, 38, 43, 154, 200–205, 208, 269, 281, 373

H

- Hexapeptide 104, 106
- High throughput screening28–30
- Human norovirus137–151

I

- IgSelect.....155–159, 162, 163
- Immobilized metal-affinity chromatography (IMAC) 44, 260–262, 264, 266
- Immune complexes (ICs)33, 34, 133, 333–338
- Immune-informatics.....45
- Immune system v, 1–23, 25, 30, 31, 40, 45, 235, 269, 270, 327, 328, 333, 341, 354, 373, 374
- Immunity.....2, 3, 8, 30, 36, 42, 137, 288, 301, 354
- Immunoaffinity purification41, 44, 235–242
- Immunoassays 359, 364, 366
- Immuno-electrophoresis (IE) 119–123, 126–128, 133, 134
- Immuno-peptidomics 43, 245, 247
- Immunoprecipitates..... 119, 120, 125, 129, 133, 302, 305
- Immunoprecipitation (IP) 119, 125, 133, 138, 245, 246, 248–251, 254, 255, 260, 261, 263, 266, 302, 304, 319
- Immunoproteomicsv, 25–45, 59–76, 327–332, 353–367, 371–376
- Immunoreactivity 60, 64, 67–69, 75
- Immunotherapiesv, 21, 22, 32, 43, 44, 214, 260, 372, 374, 376

- Infectious diseases v, 22, 29–31, 34, 42, 60, 103, 140, 184, 199, 328, 333
- Inflammation 5, 8, 13–16, 36, 309–324
- Influenza 22, 29, 216, 221, 227, 233, 353–367
- Influenza A viruses 229–231
- Innate immunity 2
- Intact cells 340
- Intact LC-MS 157, 159, 161
- Integrative platform 327–332
- Intercellular 11, 321
- L**
- Liquid biopsies 376
- Liquid chromatography tandem mass spectrometry (LC-MS/MS) 98, 154, 246, 250, 252–256, 260, 262, 265, 302, 304, 305, 314
- Live vaccine strain (LVS) 62, 69, 288, 296
- Low abundance protein enrichment 104, 105, 117
- Low molecular weight proteome 95–101
- Luciferase immunoprecipitation system (LIPS) assay 137–151
- Luminex 79, 80, 82–84, 87, 89
- M**
- Macrophages 2, 5, 6, 8, 10, 14, 15, 40, 44, 340–342, 347, 350, 374
- Major histocompatibility complex (MHC) v, 8, 26, 213, 235, 245, 260, 269, 287, 301, 328
- Major histocompatibility complex (MHC)-associated glycopeptides 270, 273–277
- Major histocompatibility complex (MHC)-associated peptide isolation 40, 41, 241, 250, 262, 271
- Major histocompatibility complex (MHC)-binding peptides 214, 245
- Major histocompatibility complex (MHC) epitope prediction 287–299
- Major histocompatibility complex (MHC) ligandome 302
- Major histocompatibility complex (MHC) ligands 288, 289, 301
- Major histocompatibility complex (MHC) peptides 16, 26, 40–44, 235, 241, 245–256, 259–261, 277, 278, 282, 283, 296, 302, 304
- Mass spectrometry (MS) v, 26, 59, 95, 104, 120, 154, 171, 202, 235, 245, 259, 270, 302, 313, 334, 339, 353, 374
- Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) 202, 205, 339
- Mild acid elution (MAE) 41, 245, 246, 249, 251, 255
- Molecular modeling 269–283
- Multiplex assay 87
- N**
- Nano-liquid chromatography-tandem mass spectrometry (nano-LC-MS/MS) 311, 314, 316–317, 320, 323, 334–337
- Neoantigens 43, 45, 214, 255, 256, 260, 328
- NetMHC 302–305
- P**
- Papain 334, 336, 337
- Peptide elution 40, 41
- Peptide library 108, 213–233
- Phage-display library 181–197
- Phosphorylation 196, 224, 259, 265
- Post translational modification (PTM) 30, 33, 38, 43, 200, 201, 269
- Protein depletion 108
- Protein-protein interactions 39, 310, 311, 314, 315, 318–321
- Proteomics v, 22, 25, 68, 95, 103, 154, 168, 256, 303, 309, 329, 333, 340, 373
- ProteoMiner™ 103–117
- R**
- Receptor identification 167
- Renilla luciferase (Ruc) 138, 141–143, 146–149
- S**
- Serological analysis of recombinant cDNA expression libraries (SEREX) 32, 33, 60, 199
- Serological proteome analysis (SERPA) 27, 28, 59–76
- Serum 13, 29, 60, 90, 96, 103, 132, 137, 154, 183, 206, 247, 260, 333, 340, 350
- biomarkers 39, 104
- stability 155
- Sialylation 208
- SpectMHC 302–306
- Streptococcus pneumoniae* 32, 183, 184, 186, 189–196
- Surveillance 8, 36, 302, 328, 353–355, 366
- T**
- Target prioritization 310
- T-cell 8, 26, 213, 235, 260, 269, 287, 301, 311, 372
- Therapeutics 28, 34, 42, 153–165, 214, 245, 302, 309–324, 372, 374, 376
- Tularemia 61, 64, 288
- V**
- Vaccines 1, 26, 60, 183, 199, 214, 245, 328, 353
- Virus 29, 41, 137, 138, 216, 221, 229, 231, 353–359, 363, 366
- W**
- Western blotting 25, 27, 59–61, 66–69, 74, 138, 156, 162–164, 246, 254, 263, 266, 320, 321
- Y**
- Yeast display 216, 217, 226, 229–231